A meta-analysis and systematic review evaluating the use of erythropoietin in total hip and knee arthroplasty

Therapeutics and Clinical Risk Management

Volumn 14, Issue , 2018, Pages 1191-1204

  Li, Yi ^a   Yin, Pengbin ^a   Lv, Houchen ^a   Meng, Yutong ^a   Zhang, Licheng ^a   Tang, Peifu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Allogeneic transfusion; Autologous blood donation; Erythropoietin; Hemoglobin; Total hip arthroplasty; Total knee arthroplasty

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ALLOGENIC BLOOD TRANSFUSION; BLOOD DONOR; BLOOD TRANSFUSION; DRUG EFFICACY; DRUG USE; HOSPITAL DISCHARGE; HUMAN; META ANALYSIS; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE AUTOLOGOUS BLOOD DONATION; PREOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TOTAL KNEE ARTHROPLASTY; VENOUS THROMBOEMBOLISM;

EID: 85049835353     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S159134     Document Type: Review

References (42)

1. Tran DHD, Wong GT, Chee YE, Irwin MG. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period. Expert Opin Biol Ther. 2014;14(1):51–61.
2. Zhao Y, Jiang C, Peng H, Feng B, Li Y, Weng X. The effectiveness and safety of preoperative use of erythropoietin in patients scheduled for total hip or knee arthroplasty. Medicine. 2016;95(27):e4122.
3. Voorn VMA, van der Hout A, So-Osman C, et al. Erythropoietin to reduce allogeneic red blood cell transfusion in patients undergoing total hip or knee arthroplasty. Vox Sang. 2016;111(3):219–225.
4. Alsaleh K, Alotaibi GS, Almodaimegh HS, Aleem AA, Kouroukis CT. The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty. J Arthroplasty. 2013; 28(9):1463–1472.
5. Stivelman JC. Target-based anemia management with erythropoiesis stimulating agents (risks and benefits relearned) and iron (still more to learn). Semin Dial. 2017;30(2):142–148.
6. Elliott S, Tomita D, Endre Z. Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrol. 2017;18(1):14.
7. Foley RN. Emerging erythropoiesis-stimulating agents. Nat Rev Nephrol. 2010;6(4):218–223.
8. Mares JM, Foley LS, Bell MT, et al. Erythropoietin activates the phos-porylated cAMP [adenosine 3′5′ cyclic monophosphate] response element-binding protein pathway and attenuates delayed paraplegia after ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2015; 149(3):920–924.
9. Yamanaka K, Eldeiry M, Aftab M, et al. Optimized induction of beta common receptor enhances the neuroprotective function of erythropoietin in spinal cord ischemic injury. J Thorac Cardiovasc Surg. Epub February 9, 2018.
10. Smith PD, Puskas F, Fullerton DA, et al. Attenuation of spinal cord ischemia and reperfusion injury by erythropoietin. J Thorac Cardiovasc Surg. 2011;141(1):256–260.
11. Robertson CS, Hannay HJ, Yamal JM, et al. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury. JAMA. 2014;312(1):36.
12. Gonzalez-Porras JR, Colado E, Conde MP, Lopez T, Nieto MJ, Corral M. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med. 2009;19(1): 35–42.
13. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma. 2003;54(5):908–914.
14. Keating EM, Ritter MA. Transfusion options in total joint arthroplasty. J Arthroplasty. 2002;17(4 Suppl 1):125–128.
15. Keating EM, Callaghan JJ, Ranawat AS, Bhirangi K, Ranawat CS. A randomized, parallel-group, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty. J Arthroplasty. 2007;22(3):325–333.
16. Jans Ø, Jørgensen C, Kehlet H, Johansson PI; Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group. Role of preoperative anemia for risk of transfusion and postoperative morbidity in fast-track hip and knee arthroplasty. Transfusion. 2014;54(3):717–726.
17. Jorgensen CC, Kehlet H; Lundbeck Foundation Centre for Fast-track Hip and Knee replacement collaborative group. Early thromboembolic events ≤1 week after fast-track total hip and knee arthroplasty. Thromb Res. 2016;138:37–42.
18. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(90231):I9–I16.
19. Bernabeu-Wittel M, Romero M, Ollero-Baturone M, et al. Ferric carboxymaltose with or without erythropoietin in anemic patients with hip fracture: a randomized clinical trial. Transfusion. 2016;56(9): 2199–2211.
20. So-Osman C, Nelissen RG, Koopman-van Gemert AW, et al. Patient blood management in elective total hip-and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology. 2014; 120(4):839–851.
21. Buljan M, Nemet D, Golubic-Cepulic B, Bicanic G, Tripkovic B, Delimar D. Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. Int Orthop. 2012;36(4):703–709.
22. Na HS, Shin SY, Hwang JY, Jeon YT, Kim CS, Do SH. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty (CME). Transfusion. 2011;51(1):118–124.
23. Moonen AF, Thomassen BJ, Knoors NT, van Os JJ, Verburg AD, Pilot P. Pre-operative injections of epoetin-alpha versus post-operative retransfusion of autologous shed blood in total hip and knee replacement: a prospective randomised clinical trial. J Bone Joint Surg Br. 2008;90(8):1079–1083.
24. Deutsch A, Spaulding J, Marcus RE. Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty. J Arthroplasty. 2006;21(5):628–635.
25. Rosencher N, Poisson D, Albi A, Aperce M, Barré J, Samama CM. Two injections of erythropoietin correct moderate anemia in most patients awaiting orthopedic surgery. Can J Anaesth. 2005;52(2):160–165.
26. Weber EW, Slappendel R, Hémon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol. 2005;22(4):249–257.
27. Hardwick ME, Morris BM, Colwell CW Jr. Two-dose epoetin alfa reduces blood transfusions compared with autologous donation. Clin Orthop Relat Res. 2004;423:240–244.
28. Avall A, Hyllner M, Bengtson JP, Carlsson L, Bengtsson A. Recombinant human erythropoietin in preoperative autologous blood donation did not influence the haemoglobin recovery after surgery. Acta Anaesthesiol Scand. 2003;47(6):687–692.
29. Bezwada HP, Nazarian DG, Henry DH, Booth RE Jr. Preoperative use of recombinant human erythropoietin before total joint arthroplasty. J Bone Joint Surg Am. 2003;85-A(9):1795–1800.
30. Aksoy MC, Tokgozoglu AM. Erythropoietin for autologous blood donation in total hip arthroplasty patients. Arch Orthop Trauma Surg. 2001;121(3):162–165.
31. Olijhoek G, Megens JG, Musto P, et al. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion. 2001;41(7):957–963.
32. Gombotz H, Gries M, Sipurzynski S, Fruhwald S, Rehak P. Preoperative treatment with recombinant human erythropoietin or predeposit of autologous blood in women undergoing primary hip replacement. Acta Anaesthesiol Scand. 2000;44(6):737–742.
33. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 2000;133(11):845–854.
34. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg Am. 1996;78(1): 62–72.
35. Hasegawa Y, Takamatsu J, Iwase T, Iwasada S, Kitamura S, Iwata H. Effects of recombinant human erythropoietin on thrombosis and fibrin-olysis in autologous transfusion for hip surgery. Arch Orthop Trauma Surg. 1999;119(7–8):384–387.
36. Wurnig C, Schatz K, Noske H, et al. Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res. 2001;33(5–6):303–310.
37. Stowell CP, Chandler H, Jové M, Guilfoyle M, Wacholtz MC. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics. 1999;22(Suppl 1):s105–s112.
38. Mercuriali F. Epoetin alfa increases the volume of autologous blood donated by patients scheduled to undergo orthopedic surgery. Semin Hematol. 1996;33(2 Suppl 2):10–14.
39. Price TH, Goodnough LT, Vogler WR, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion. 1996;36(1):29–36.
40. Goodnough LT, Price TH, Friedman KD, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion. 1994;34(1):66–71.
41. Beris P, Mermillod B, Levy G, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sang. 1993;65(3):212–218.
42. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Canadian Orthopedic Perioperative Erythropoietin Study Group. Lancet. 1993;341(8855):1227–1232.